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Available online 22 June 2017Background: The longitudinal course of the negative symptoms subdomains social amotivation (SA) and expres-
sive deficits (ED) remains largely unknown. We investigated i) the longitudinal course of SA and ED subdomain
scores, ii) whether subgroups based on the course of SA and ED subdomain scores could be identified, iii) whether
baseline SA and ED subdomain scores were related to functioning and quality of life six years later and iv) the lon-
gitudinal relationship between subgroups and outcomes.
Methods:Measurements at baseline, three and six years from 1067 patients participating in the Genetic Risk and
Outcome of Psychosis (GROUP) projectwere used.We appliedmixedmodels analysis, regression analysis and tra-
jectory analyses.
Results: SA and ED subdomain scores decreased over time. Within both subdomains, four subgroups were identi-
fied: for both SA and ED a steady low course (±60%), increased (±15%) and decreased course (±15%).Within SA
only, a higher level decreased course (±6%) and within ED only, a course with relatively stable high ED scores
(±6%) was found. Lower symptom levels at baseline were related to better functioning (SA & ED) and quality
of life (SA) at six years. Overall, low SA and low ED subgroups showed better outcomes than the other subgroups.
Conclusion: In many patients the course of negative symptoms is unstable and related to the course of outcome.
Patients who do show steady low negative symptom levels (60%) may complicate the interpretation of treatment
evaluation studies, as they may average out possible effects in subgroups with fluctuating symptom levels.






Although positive symptoms are usually most dominant in the acute
phase of psychotic disorder, negative symptoms are considered to be
most disabling, due to their persistent nature and profound relationship
with poor functional outcomes (Bobes et al., 2010; Ventura et al., 2009).
Despite the growing body of research, both pharmacological andion, Lentis Psychiatric Institute,
rsity.nl (A.P.M. Stiekema).psychosocial interventions only have a limited effect on reducing nega-
tive symptoms (Savill et al., 2014). The heterogeneous nature of negative
symptoms makes them difficult to treat. Grouping negative symptoms
into two subdomains can diminish this heterogeneity (Foussias et al.,
2014b; Messinger et al., 2011). One possibility of grouping symptoms
is distinguishing two subdomains on the basis of the Positive and Nega-
tive Syndrome Scale (PANSS; Kay et al., 1987): social amotivation (SA)
and expressive deficits (ED) (Liemburg et al., 2013; Stiekema et al.,
2016). SA encompasses social and emotional withdrawal and reflects di-
minished interest in or affective commitment to the social environment.
ED involves blunted affect, poverty of speech, andmotor retardation. The
robustness of such subdomains is illustrated by the finding that similar
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Negative Symptoms (SANS; Andreasen, 1983) even though the composi-
tion of both subdomains differs somewhat depending on the instrument
that is used to assess symptoms (Foussias et al., 2014a; Liemburg et al.,
2013; Stiekema et al., 2016). This difference most importantly concerns
the allocation of the apathy item. When the PANSS is used, the factor
structure appoints the “apathy item” to the ED subdomain (Liemburg
et al., 2013; Stiekema et al., 2016). When the SANS (Andreasen, 1983)
is used, the “apathy item” is appointed to SA (Foussias et al., 2014a).
SA is thought to be the result of a deficit in anticipating on pleasurable
events and activities (Buck and Lysaker, 2013; Foussias et al., 2014b). ED
reflects a diminished expressive responsiveness that is observed in verbal
and non-verbal communication, caused by or related to, neurocognitive
deficits (Bell et al., 2013; Ergül and Üçok, 2015; Hartmann-Riemer et
al., 2015; Liemburg et al., 2013). There is ample evidence for a strong re-
lationship between SA and global functioning (Fervaha et al., 2014b;
Foussias et al., 2011; Rocca et al., 2014). The associations of EDwith func-
tioningwere found to be less strong (Foussias et al., 2011; Galderisi et al.,
2014; Strauss et al., 2013).We recently reported that ED, but not SA, pre-
dicted residential living status in a chronic populationwith psychotic dis-
orders (Stiekema et al., 2016), indicating that EDmay in fact be related to
daily functioning. However, the extent to which scores on subdomains
are consistent over time remains unclear. The few studies that have in-
vestigated the longitudinal course of the ED and SA subdomains showed
mixed results, varying from long-term stability of both domains
(Galderisi et al., 2013), of the expressive but not the amotivation domain
(Ergül and Üçok, 2015), and vice versa (Norman et al., 2015).
In the current study, we investigated the longitudinal course of
SA and ED subdomain scores. Secondly, we examined whether
subgroups with different longitudinal courses of SA and ED could
be identified. Thirdly, we investigated whether baseline levels of SA
and ED were related to functioning (global functioning, social
functioning, independent living, and engagement in work or study)
and quality of life six years later. Finally, we assessed the
longitudinal relationship between subgroups and functioning and
quality of life. Following up on our previous findings, we
hypothesized that both subdomains would be related to global
functioning and engagement in work or study, that SA would be
most strongly related to social functioning and quality of life, while
ED would be related to non-independent living status.
2. Methods
2.1. Study design
We used data from the Genetic Risk and Outcome of Psychosis
(GROUP) project, in which outpatients and inpatients with a psychotic
disorder between 16 and 50 years were recruited from 36 sites in the
Netherlands. Between April 2004 and December 2013, participants
were assessed at baseline and three and six years thereafter. Study pro-
cedures have been described in detail elsewhere (Korver et al., 2012).
2.2. Participants
The GROUP sample consisted of 1119 patients and 586 healthy con-
trols at baseline (Korver et al., 2012). Fifty-three patients were excluded
because their diagnosis was missing (n = 4), unclear (n = 21) or other
than primary psychotic (n=27) leading to an inclusion of 1067 patients
in the analysis (see Table 1 for demographic characteristics).
2.3. Assessment
Psychopathology in the pastweekwas assessedwith the Positive and
Negative Syndrome Scale (PANSS, Kay et al., 1987). For each patient, SA
(sum score of items N2, N4 and G16) and ED (sum score of items N1,
N3, N6, G5, G7 and G13) subdomains scores were calculated at baseline(Liemburg et al., 2013). Global functioning in the past month was mea-
sured with the Global Assessment of Functioning Disability scale (GAF-
D, American Psychiatric Association, 2000)), on an anchored scale from
1 (most severe) to 100 (excellent functioning). Both the PANSS and the
GAFwere assessed by a trained interviewer (research assistant, psychol-
ogist, psychiatrist, nurse or PhD student).
Social functioning at the moment of assessment was measured with
the Social Functioning Scale (SFS) (Birchwood et al., 1990), filled out by
the participant at three and six years. The SFS score was computed as
the mean of the seven subscales scaled scores.
Current living situation, employment and educational activities were
assessed at eachmeasurement as part of the demographical information.
Independent living (single or with partner or own family vs. living with
parents or other familymembers or sheltered living) and engagement in
work or study (work/study vs. no work/study) were also used as func-
tional outcome measures.
Quality of life was assessed with the World Health Organization
Quality of Life-BREF (WHO-QOL-BREF, Trompenaars et al., 2005)), a
self-report questionnaire based on the past two weeks, including four
domains of quality of life: physical health, psychological, social relation-
ships, and environment.
Neurocognition was based on a composite score (mean z-scores) of
the Continuous Performance Test, Word Learning Task immediate recall
and delayed recall and recognition, andWAIS-III Symbol Substitution, In-
formation, Arithmetic and Block Design. Healthy control subjects were
used to obtain age and gender specific z-scores for patients.
2.4. Statistical analysis
2.4.1. Evaluation of missing data
Baseline characteristics of completers versus non-completers (pa-
tientswhodid not participate in the three and/or six-yearmeasurement)
were compared using the Kruskal-Wallis test for continuous variables
and Chi-square tests for categorical variables. Multiple imputation was
applied to address missing data (due to absenteeism, attrition, or a fail-
ure to complete the questionnaire on time), since ignoring missing
data may yield biases as it does not differentiate missing at random
mechanism (Little and Rubin, 2002) (see S1 for details). For all analyses
two-tailed tests, withα=0.05were performed using Statistical Analysis
System (SAS), version 9.4 (SAS Institute Inc., 2013).
2.4.2. Longitudinal course of SA and ED subdomain scores
The longitudinal course of SA and ED subdomain scores over time
was assessedwith a linearmixedmodel applied on imputeddata, includ-
ing only the fixed effect of time as a categorical independent variable. All
analyses were conducted for SA subdomain scores and ED subdomain
scores separately.
2.4.3. Identification of subgroups based on SA and ED subdomain scores
Subgroups within both SA and ED subdomains were identified
with group-based trajectory modeling (GBTM), a semi-parametric
statistical method for analyzing developmental trajectories (Jones
et al., 2001; Niyonkuru et al., 2013) (See S2 for details). Clusters of
patients following similar patterns based on the SA or ED subdomain
scores will be referred to as SA or ED subgroups, respectively. Differ-
ences between the identified subgroups on baseline demographic
and clinical characteristics were examined using the Kruskal-Wallis
test for continuous variables and Chi-square or Fishers exact tests
for categorical variables. Pairwise comparisons were corrected for
multiple testing using Bonferroni correction.
2.4.4. Associations between subdomain scores and outcome at six years
To investigate the relationship between baseline SA and ED
subdomain scores and functioning and quality of life six years later,
multiple linear regression analysis was conducted on six year imput-
ed GAF, SFS andWHO-QOL scores. Logistic regression was applied on
Table 1
Baseline demographic and clinical characteristics of participants (n = 1067).
N (total sample) Mean (standard deviation) or percentage Completers Non-completers p-Valuee
Demographics
Age, years 1059 27.1 (7.24) 27.4 (7.35) 26.7 (7.05) 0.104
Gender, male 1067 77.1% 76.2% 78.5% 0.414
Educationa 1015 4.0 (2.06) 4.2 (2.00) 3.8 (2.11) 0.001
Caucasian 823 79.2% 84.3% 71.5% b0.001
Marital status 1051
Not married 929 88.4% 88.3% 88.5% 1.000
Married/living together 93 8.8% 9.3% 8.1% 0.579
Divorced/widowhood 29 2.8% 2.4% 3.3% 0.344
Residential status 991
Single or with partner/family 433 43.7% 45.4% 41.1% 0.409
With parent(s) or sheltered living 494 49.8% 50.1% 49.5% 0.791
Other 64 6.5% 4.5% 9.5% 0.002
Clinical characteristics
Diagnosis 1067
Schizophrenia 722 67.7% 65.6% 70.8% 0.083
Schizo-affective disorder 120 11.2% 11.9% 10.3% 0.431
Psychosis NOS 113 10.6% 11.9% 8.6% 0.104
Schizophreniform 62 5.8% 6.1% 5.4% 0.690
Other 50 4.7b% 4.6% 4.9% 0.770
Duration of illness, years 1011 4.2 (3.83) 4.5 (4.09) 3.8 (3.33) 0.005
Recent onset psychosisc 1067 32.6% 69.5% 64.3% 0.083
Number of hospitalizations 895 1.9 1.9 (2.41) 1.9 (2.01) 0.540
Number of psychotic episodes 1041 1.7 1.8 (1.09) 1.7 (1.20) 0.115
GAF 970 54.4 (16.03) 56.3 (15.76) 51.4 (16.02) b0.001
SFS totald – – – – –
PANSS total 1014 54.9 (16.77) 52.95 (15.97) 57.81 (17.54) b0.001
PANSS positive 1015 12.7 (5.33) 12.24 (5.14) 13.49 (5.55) b0.001
PANSS negative 1012 14.1 (6.01) 13.49 (5.67) 14.99 (6.40) b0.001
PANSS general 1014 28.1 (8.40) 27.21 (7.98) 29.33 (8.86) b0.001
PANSS social amotivation 1001 6.2 (3.09) 6.0 (3.00) 6.5 (3.21) 0.025
PANSS expressive deficits 996 10,79 (4.76) 10.4 (4.49) 11.3 (5.10) 0.010
WHO-QOL total 946 88.4 (14.82) 89.11 (14.66) 87.25 (15.04) 0.054
GAF: Global Assessment of Functioning; SFS: Social Functioning Scale; PANSS: Positive and Negative Syndrome Scale; WHO-QoL: World Health Organization Quality of Life.
a Education (Verhage): range 1 (no education), 2 (education but no diploma), 3–5 (school diploma) to 8 (university degree).
b 32 Brief psychotic disorder (2.9%), 22 delusional disorder (2.1%), 1 psychotic disorder due to medical condition (0.1%).
c First psychotic episode b2 years prior to baseline measurement.
d The SFS was only administered at the 3 and 6 year measurements.
e Kruskal-Wallis test were used for continuous variables and Chi-square tests for categorical variables.
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Baseline SA and ED were entered into the first block, gender, dura-
tion of illness, positive symptoms (PANSS positive subscale), and
neurocognition (composite score) into the second block.
2.4.5. Longitudinal relationship between SA and ED subdomain scores and
outcomes
Associations between subgroups and continuous outcomes were
analyzed with linear mixed models; parameter estimates and their
variance components were estimated with restricted maximum
likelihood (REML). Associations between subgroups and imputed
categorical outcomes were analyzed with generalized linear mixed
models (random intercept (patients) mixed model); parameters
and their associated standard errors were estimated using an
adaptive Gaussian quadrature with 10 quadrature points. All
independent variables (including subgroups within subdomains
and time as a categorical measure) were included in the statistical
model as fixed effects. Gender, duration of illness, positive
symptoms, and neurocognition were included in the model to con-
trol for these effects. Pooled Type-III tests of fixed effects p-values
(Li et al., 1991; Rubin, 1987) were used to conclude the marginal
effects on different outcomes. Mean differences of SA or ED
subgroups were compared and corrected for multiple testing using
Bonferroni correction.
3. Results
Baseline characteristics are shown in Table 1. Compared to com-
pleters, non-completers on average had a significantly shorter durationof illness, lower education levels, lower GAF scores andmore severe psy-
chotic symptoms, including higher SA and ED subdomain scores (see
Table 1). Supplementary Table 1 shows an overview of missing data.
The percentage of patients with missing data at both three and six
years follow up was 25.1% for the SA subdomain scores and 25.5% for
the ED subdomain scores.
3.1. Longitudinal course of SA and ED subdomain scores
SA and ED subdomain scores both significantly reduced over time
(overall pooled Type-III fixed effect F2, 2120= 65.69, p b 0.001; F2, 2120
= 84.90, p b 0.001) (See the overall profile in Fig. 1).
3.2. Identification of subgroups based on SA and ED subdomain scores
Within each subdomain, four subgroups with a different course of
negative symptoms could be identified (see Fig. 1 and Supplementary
Table 2). For SA, the majority of the patients (58%) showed a steady
low level of SA symptoms across all time points (low SA subgroup). In
21% of the patients SA subdomain score started high at study entry and
decreased over time (decreased-low SA subgroup). The same pattern
but on a higher level was found for 6% of the patients (decreased-high
SA subgroup). Conversely, 15% of the patients started out with low SA
subdomain scores that increased over time (increased SA subgroup)
(Fig. 1).
Similarly, for ED the majority of patients (64%) showed a steady and
low ED subdomain score over time (low ED subgroup). In 17% of the
patients a high ED subdomain score at the start decreased over time
(decreased ED subgroup). Conversely, 14% of the patients a low ED
Fig. 1. Subgroups based on the course of SA (left) and ED (right) subdomain scores over a period of 6 years.
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group). Finally, in the ED subdomain, and additional small subgroup
(6%) was identified with a steady high ED subdomain score over time
(high ED subgroup) (Fig. 1).
Although subgroup differences in baseline characteristics are not all
significantly different, a pattern is visible in Table 2. For example, the
low SA and ED subgroups show the highest level of education and the
highest percentage of married or living together, the high SA and ED
subgroups show the lowest education level and the lowest percentage
of married or living together and the other groups show frequencies in
between.
3.3. Associations between subdomain scores and outcome at six years
Lower baseline SA subdomain scores predicted a higher level of
global functioning (GAF; β = −0.73, t = −3.46, p = 0.001), social
functioning (SFS; β= −0.70, t = −6.30, p b 0 0.001), better quality of
life (β = −0.64, t = −3.62, p b 0.001) and engagement in work or
study (β=−0.08, t=−2.18, p= 0.03) six years later. Lower baseline
ED subdomain scores predicted a higher level of global functioning
(GAF; β = −0.36, t = −2.09, p = 0.04) and social functioning (SFS;
β = −0.32, t = −3.40, p = 0 0.002) six years later.
3.4. Longitudinal relationship between SA and ED subdomain scores and
outcomes
Overall, our data demonstrate a clear pattern distinguishing SA and
ED subgroups with low or decreasing subdomain scores from the SA
and ED subgroups with high or increasing subdomain scores. The former
generally demonstrate an improvement in outcome variables, whereas
the latter subgroups show a less favorable course of outcome (see Fig.
2). Looking at the outcome at the individual timepoints, ourmost impor-
tant findings show that within the SA subdomain the low SA subgroup
scored higher (better) than the other SA subgroups on the GAF, SFS
and the WHOQOL-BREF at all time points. Within the ED subdomain,
the low ED subgroup scored higher (better) than the other subgroups
at all time points on the GAF and SFS, except for the six-year measure-
ment compared to the decreased ED. Overall, the living situation in the
low ED subgroup improved, but patients remained less independent
than patients in the other ED subgroups, which was significant at study
entry (low ED vs decreased ED) and at 3 years (low ED vs high ED).
(See Supplementary Table 3 for details).
Longitudinally, we showed significant differences between
subgroups within SA and ED subdomains with regard to outcome(See Table 3 and Fig. 2). In general, patients with steady low SA or
ED subdomain scores, show the most favorable course of outcome.
Patients in whom SA and ED scores decrease generally improve
over time on all outcomemeasures. The course of outcome is least fa-
vorable for the subgroups with increased SA and ED subdomain
scores, who tend to worsen on outcomes, and for the subgroup
with steady high ED subdomain scores, who show the lowest out-
come scores on all measures except quality of life.
4. Discussion
In the current study, we aimed to shed more light on the course of
negative symptoms on the subdomains SA and ED as well as the rela-
tionship over time with outcome. To this end, we (1) examined and
mapped the course of SA and ED over a period of six years. We further
disentangled the heterogeneity of negative symptoms by (2) assessing
whether subgroups based on the course of SA and ED over time could
be distinguished. We then investigated (3) whether SA and ED
subdomain scores at baseline were related to functioning and quality
of life six years later. Finally, we investigated (4) the course of outcome
over six years for the identified subgroups and to what extent this
course differed between subgroups.
Most importantly, we demonstrated that though overall symptoms
in both the SA and ED subdomain scores decreased over the course of
six years, subgroups within the subdomains SA and ED show a less ho-
mogenous course of negative symptoms over time. We showed that
baseline SA and ED subdomain scores were related to functioning
(SA&ED) and quality of life (SA) six years later. Finally, we demonstrat-
ed a differential pattern for outcome over a period of six years for the
different subgroups within SA and ED.
4.1. Longitudinal course and subgroups of SA and ED
Overall, our findings suggest a decrease of SA and ED subdomain
scores over time. According to the literature, improvement of negative
symptoms often takes place in the first few years of illness (Eaton et
al., 1995; Evensen et al., 2012; Hovington et al., 2012) and an increase
in negative symptoms is predominantly found in chronic patients
(Chang et al., 2011). By introducing subgroups, we were able to
demonstrate a more detailed account of negative symptom
development. Though the majority of patients showed a steady low
score on the SA subdomain (58%) and ED subdomain (64%),
approximately one third of the patients either improved or decreased
on SA and ED subdomain scores over time. For a small, but significant,
Table 2
Baseline demographic and clinical characteristics per subgroup when analyzed for the course of negative symptomswithin the SA subdomain scores and similarly when analyzed for the
course within the ED subdomain scoresa.


















Age, years 26.9 (7.22)# 26.8 (7.16) 28.4 (7.50) 28.4 (6.95) 27.4# 25.4 (6.43)† 28.5 (7.14)‡ 26.0 (7.70)
Gender, male 73.3‡ 82.1 81.7 94.4 75.0‡ 82.2 76.3 89.7
Education 4.2 (2.03)‡ 3.8 (2.11) 3.7 (2.01) 3.4 (1.95) 4.2⁎ 3.7 (2.04) 3.7 (2.03) 3.4 (2.10)
Caucasian 82.1† 77.4 70.1 71.7 80.3‡ 80.1 77.5 66.1
Marital status
Not married 86.6 90.0 92.4 94.4 86.6# 82.2 87.6 94.8
Married/living together 10.0 8.1 6.8 1.9 10.0 17.8 10.6 3.4
Divorced/widowhood 3.3 1.8 0.8 3.7 3.4 1.1 1.8 1.7
Residential status
Single 33.9 32.4 34.5 34.6 36.4 27.5 32.1 24.1
With parent(s) 39.7 39.1 40.9 42.3 37.7 43.9 42.5 48.1
With partner/family 11.7 8.2 7.3 1.9 12.0# 5.3 8.5 3.7
Sheltered living 8.4 13.0 11.8 13.5 8.6 11.7 12.3 16.7
Other 6.3 7.2 5.5 7.7 5.3# 11.7 4.7 7.4
Clinical characteristics
Diagnosis
Schizophrenia 61.6⁎ 74.9 80.8 83.3 62.8⁎ 73.9 79.8 84.5
Schizo-affective disorder 12.5 10.3 5.8 11.1 13.0 7.8 7.9 6.9
Psychosis NOS 12.5‡ 10.3 5.0 – 11.7 10.6 6.1 5.2
Schizophreniform 7.0# 2.2 5.8 5.6 6.0 5.6 6.1 3.4
Other 6.3 2.3 2.5 – 6.5† 2.1 – –
Duration of illness, years 4.2 (3.82) 3.9 (3.23) 4.7 (4.57) 5.1 (4.27) 4.3 3.8 (3.37) 4.5 (3.90) 4.1 (3.79)
Recent onset psychosis 32.5 31.8 35.8 29.6 31.9 36.1 33.3 29.3
Number of hospitalizations 1.7 (1.92) 2.1 (2.72) 2.2 (3.00) 2.0 (2.21) 1.8 2.2 (3.21) 1.8 (1.53) 1.9 (2.32)
Number of psychotic episodes 1.8 (1.16) 1.63 (1.07) 1.6 (1.03) 1.8 (1.33) 1.8 1.7 (1.07) 1.6 (0.86) 1.7 (1.24)








































SA scores 4.4 (1.48)⁎ 9.6 (1.57)⁎ 6.0 (1.83)⁎ 12.9 (2.26)⁎ 5.2 (2.57)⁎ 8.5 (2.67)† 6.7 (2.68)⁎ 10.0 (3.64)
ED scores 9.1 (3.61)⁎ 13.7 (4.84)⁎ 11.6 (4.30) 16.7 (5.87) 8.1 (2.12)⁎ 16.6 (2.41)† 12.0 (2.65)⁎ 21.3 (3.39)
GAF 58.7 (16.41)⁎ 47.1 (12.16)‡ 51.1 (12.95)‡ 40.4 (9.63)⁎ 58.2 (15.69)⁎ 46.1 (13.18) 51.0 (14.25)‡ 40.6 (12.39)
PANSS total 47.8 (12.98)⁎ 67.5 (14.90)⁎ 57.6 (12.7)⁎ 78.6 (16.85)⁎ 48.6 (13.57)⁎ 68.4 (14.11)† 58.5 (12.44)‡ 79.1 (16.69)
PANSS positive 11.6 (4.61)⁎ 14.8 (6.08) 13.3 (4.93) 16.3 (6.47) 12.1 (5.17)⁎ 14.0 (5.68) 13.4 (4.69) 15.5 (5.7)
PANSS negative 11.2 (4.10)⁎ 19.2 (4.98)⁎ 14.9 (4.67)⁎ 24.0 (5.80)⁎ 11.1 (3.82)⁎ 20.5 (3.95)† 15.7 (4.09)‡ 25.2 (5.66)
PANSS general 25.0 (6.86)⁎ 33.47 (8.08)† 29.4 (6.73)⁎ 38.2 (9.14) 25.4 (6.97)⁎ 33.9 (8.33)† 29.5 (6.61)‡ 38.4 (9.05)
WHO-QOL-BREF 91.6 (14.50)⁎ 83.7 (13.92) 84.0 (13.0) 78.9 (14.45) 90.2 (15.15)⁎ 85.5 (13.53) 84.1 (12.58) 84.1 (14.97)
Neurocognition −0.50 (0.61)† −0.64 (0.64) −0.55 (0.69) −0.65 (0.72) −0.47 (0.58)⁎ −0.74 (0.66) −0.67 (0.70) −0.73 (0.62)
a Differences between the subgroups were tested using the Kruskal-Wallis test for continuous variables, the Chi-square test for categorical variables and the Fishers exact test when
expected counts were less than five. p-Values were multiplied by the number of comparisons (six) to correct for inflated experiment wise error. For the sake of clarity, significant differ-
ences between two groups are indicated only in the first column of the groups.
b AP = antipsychotic agents; typical APs: benperidol, bromperidol, chlorprothixene, clotiapine, fluphenazine, flupentixol, haloperidol, levomepromazine, penfluridol, perphenazine,
periciazine, pimozide, pipamperon, sulpiride, zuclopenthixol, atypical APs: amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone.
c Dose equivalents of chlorpromazine were evaluated using the methods of (Gardner et al., 2010).
⁎ Statistically significant difference compared to all other groups within the subdomain at α = 0.05.
# Statistically significant difference compared to decreased(−low) group within the subdomain at α = 0.05.
† Statistically significant difference compared to increased group within the subdomain at α = 0.05.
‡ Statistically significant difference compared to (decreased-)high group within the subdomain at α = 0.05.
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over time (high ED subgroup), which was not the case for SA. This sup-
ports previous suggestions that symptoms in the ED subdomainmay be
more persistent (Ergül andÜçok, 2015; Liemburg et al., 2013). Although
the subgroups did not differ with regard to themean duration of illness,
it seemed that the decrease and increase of negative symptoms took
place mainly in the first three years of the study. This suggests that
the variability in symptom level is most prominent within the first
years of the illness and may diminish with a longer duration of illness.
Moreover, the finding that negative symptom scores (either SA or ED)
in a third of the patients either increased or decreased over time,
suggests thatwhen these groups are bundled into larger groups changes
in negative symptoms over timemay be averaged out and thus become
invisible. This is important, as these groups may require different
treatment approaches.4.2. Associations with outcome
In general, the course of outcomes is in line with previous research
that shows that higher severity of negative symptoms is related to more
severe functional disabilities (Herbener and Harrow, 2004; Milev et al.,
2005). Overall, lower baseline scores on SA or ED subdomains predicted
better outcomes six years later. When the subdomains are further
disentangled and grouped into subgroups within SA and ED, we demon-
strated that people in the lower symptom subgroups generally showed
the best outcomes across six years and people in the high SA and ED
subgroups the worst outcome. For people in subgroups showing either
an increase or decrease in negative symptoms, this was accompanied by
a decrease or increase in functioning, respectively.
Our findings support and expand the existing evidence for the
robust relationship of SA with functioning and quality of life (Fervaha
Fig. 2. Average values of global and social functioning, quality of life, percentage of patients living independently and percentage of patients engaging inwork or study (based on imputed
data) for SA subgroups (left) and ED subgroups (right). Analyses were controlled for gender, duration of illness, positive symptoms and cognition. Bonferroni correction (p-value
multiplied by 6) was used for the pairwise comparisons. Significant differences between two subgroups are indicated only at the upper subgroup. Indicated are *significantly different
course compared to the low subgroup, between study entry and the marked time point (mixed models), significantly different level compared to § all other subgroups, #the
decreased(−low) group, †the increased subgroup and ‡ the (decreased-)high subgroup at the marked time point (pairwise comparisons).
178 A.P.M. Stiekema et al. / Schizophrenia Research 193 (2018) 173–181et al., 2014a, 2014b;Messinger et al., 2011; Strauss et al., 2013), and are
also in line with our previous study in which higher ED was associated
with global functioning in chronic patients (Stiekema et al., 2016).
While baseline ED did not predict future living status or engagement
in work or study activities, there were some significant differences in
course over time and the level of symptoms at each timepoint betweenthe subgroups. Our results indicate that SA is an important treatment
target for improving functioning and well-being, but they also point
out the importance of ED, in contrast to previous studies. Importantly,
not only did we demonstrate that different subgroups within SA and
ED can be distinguished, we also demonstrated that these subgroups
have different outcomes over the course of six years.
Table 3
Pooled parameter estimates of mixed models analyses adjusted for gender, duration of illness, neurocognition and positive symptomsa.
Living situation Work/study GAF
B SE 95% CI p-Value B SE 95% CI p-Value B SE 95% CI p-Value
Social amotivation (SA)
Intercept 0.37 0.32 −0.27; 1.01 0.253 3.25 0.27 2.71; 3.79 b0.001 74.28 1.04 72.24; 76.32 b0.001
Decreased-high SA −0.57 0.61 −1.76; 0.62 0.351 −0.92 0.40 −1.71; −0.14 0.021 −11.92 1.97 −15.78; −8.07 b0.001
Decreased-low SA −0.04 0.33 −0.68; 0.60 0.901 −0.16 0.26 −0.66; 0.35 0.545 −7.24 1.09 −9.38; −5.10 b0.001
Increased SA −0.21 0.42 −1.04; 0.62 0.620 0.06 0.35 −0.63; 0.75 0.864 −5.34 1.38 −8.04; −2.64 b0.001
Time: 3 years 0.98 0.20 0.59; 1.37 b0.001 0.11 0.23 −0.36; 0.58 0.644 4.03 0.73 2.60;5.48 b0.001
Time: 6 years 2.11 0.30 1.50; 2.72 b0.001 0.23 0.20 −0.17; 0.62 0.256 2.80 0.72 1.38;4.22 b0.001
Decreased-high SA ∗ 3 years −1.04 0.68 −2.37; 0.30 0.128 −0.40 0.56 −1.51; 0.72 0.480 −0.58 2.53 −5.58; 4.43 0.821
Decreased-high SA ∗ 6 years −0.49 0.98 −2.50; 1.51 0.617 −0.21 0.57 −1.34; 0.91 0.708 2.19 2.90 −3.63; 8.02 0.453
Decreased-low SA ∗ 3 years −0.73 0.35 −1.41; −0.04 0.039 −0.37 0.43 −1.23; 0.49 0.388 1.39 1.43 −1.44; 4.21 0.332
Decreased-high SA ∗ 6 years −0.48 0.44 −1.36; 0.40 0.280 −0.24 0.36 −0.95; 0.47 0.509 3.12 1.37 0.41; 5.82 0.024
Increased SA ∗ 3 years −0.09 0.46 −0.98; 0.81 0.851 −1.11 0.44 −1.97; −0.26 0.011 −7.42 1.66 −10.68; −4.17 b0.001
Increased SA ∗ 6 years −0.63 0.53 −1.68; 0.41 0.231 −1.33 0.42 −2.16; −0.50 0.002 −5.65 1.79 −9.20; −2.10 0.002
Expressive deficits (ED)
Intercept 0.52 0.32 −0.11; 1.15 0.107 3.40 0.28 2.86; 3.95 b0.001 75.34 1.07 73.24; 77.43 b0.001
High ED −1.17 0.59 −2.32; −0.03 0.045 −0.60 0.41 −1.42; 0.21 0.147 −11.66 1.90 −15.38; −7.93 b0.001
Decreased ED −0.94 0.35 −1.64; −0.25 0.008 −0.14 0.28 −0.69; 0.41 0.616 −8.46 1.19 −10.80; −6.11 b0.001
Increased ED −0.54 0.43 −1.38; 0.30 0.204 0.05 0.34 −0.61; 0.71 0.883 −4.85 1.43 −7.64; −2.05 b0.001
Time: 3 years 0.85 0.18 0.49; 1.21 b0.001 −0.03 0.21 −0.45; 0.39 0.896 2.89 0.68 1.55; 4.22 b0.001
Time: 6 years 1.88 0.28 1.29; 2.47 b0.001 0.02 0.21 −0.41; 0.45 0.913 1.90 0.78 0.35; 3.45 0.018
High ED ∗ 3 years −0.90 0.67 −2.23; 0.42 0.179 −0.15 0.64 −1.43; 1.14 0.820 1.99 2.58 −3.14; 7.11 0.443
High ED ∗ 6 years −0.53 0.94 −2.48; 1.42 0.579 −0.34 0.53 −1.38; 0.69 0.515 3.14 2.91 −2.73; 9.01 0.287
Decreased ED ∗ 3 years 0.14 0.38 −0.60; 0.88 0.708 −0.09 0.39 −0.86; 0.67 0.811 4.52 1.44 1.69; 7.36 0.002
Decreased ED ∗ 6 years 0.56 0.42 −0.26; 1.38 0.178 0.05 0.38 −0.70; 0.81 0.895 6.37 1.85 2.62; 10.12 0.002
Increased ED ∗ 3 years −0.50 0.46 −1.41; 0.40 0.276 −0.94 0.42 −1.77; −0.11 0.027 −3.62 1.74 −7.05; −0.19 0.039
Increased ED ∗ 6 years −0.37 0.48 −1.32; 0.57 0.439 −0.42 0.51 −1.426; 0.59 0.413 −2.51 2.02 −6.55; 1.52 0.217
SFS WHOQOL-BREF
B SE 95% CI p-Value B SE 95% CI p-Value
Social amotivation (SA)
Intercept 119.75 0.82 118.12; 121.38 b0.001 98.03 1.22 95.61; 100.46 b0.001
Decreased-high SA −8.51 1.33 −11.14; −5.89 b0.001 −9.59 2.05 −13.61; −5.57 b0.001
Decreased-low SA −3.69 0.77 −5.22; −2.16 b0.001 −6.04 1.12 −8.24; −3.84 b0.001
Increased SA −8.97 0.91 −10.76; −7.19 b0.001 −6.54 1.43 −9.34; −3.74 b0.001
Time: 3 years – – – 4.09 0.64 2.81; 5.37 b0.001
Time: 6 years 1.30 0.33 0.64; 1.96 b0.001 3.79 0.66 2.47; 5.11 b0.001
Decreased-high SA ∗ 3 years – – – – −2.33 2.13 −6.53; 1.87 0.276
Decreased-high SA ∗ 6 years 1.15 1.47 −1.86; 4.16 0.440 1.79 2.24 −2.64; 6.21 0.426
Decreased-low SA ∗ 3 years – – – – 0.57 1.20 −1.80; 2.94 0.635
Decreased-high SA ∗ 6 years 0.42 0.72 −1.02; 1.86 0.563 2.67 1.17 0.37; 4.97 0.023
Increased SA ∗ 3 years – – – – −3.49 1.47 −6.39; −0.60 0.018
Increased SA ∗ 6 years 0.24 0.75 −1.23; 1.71 0.748 −4.12 1.46 −6.99; −1.25 0.005
Expressive deficits (ED)
Intercept 120.06 0.82 118.42; 121.69 b0.001 98.38 1.25 95.92; 100.85 b0.001
High ED −7.05 1.40 −9.84; −4.25 b0.001 −3.52 2.04 −7.53; 0.48 0.085
Decreased ED −3.37 0.77 −4.89; −1.84 b0.001 −3.35 1.21 −5.73; −0.97 0.006
Increased ED −4.92 0.96 −6.81; −3.02 b0.001 −4.65 1.44 −7.47; −1.83 0.001
Time: 3 years – – – – 3.72 0.61 2.51; 4.93 b0.001
Time: 6 years 1.13 0.33 0.48; 1.77 b0.001 3.58 0.63 2.32; 4.85 b0.001
High ED ∗ 3 years – – – – −1.76 2.16 −6.03; 2.52 0.418
High ED ∗ 6 years 1.67 1.53 −1.46; 4.84 0.280 1.04 2.61 −4.25; 6.3 0.693
Decreased ED ∗ 3 years – – – – −0.05 1.34 −2.71; 2.61 0.970
Decreased ED ∗ 6 years 1.07 0.77 −0.48; 2.26 0.172 1.73 1.35 −0.94; 4.41 0.202
Increased ED ∗ 3 years – – – – −0.35 1.49 −3.27;2.58 0.817
Increased ED ∗ 6 years 1.05 0.87 −0.68; 2.78 0.230 −0.12 1.65 −3.40; 3.16 0.941
a Reference category for SA is the low SA group, reference category for ED is low ED group. Reference category for time is baseline expect for the SFS.where the three-yearmeasurement
was the reference category in the absence of a baseline measurement.
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Of the included patients in this study, about half could be classified in
both the low SA and low ED subgroup. Thus, for these patients this leaves
limited room (and need) for improvement in negative symptoms. This
poses a problem for treatment development, as it causes an increased
risk of false negative findings of treatment trials aimed at improving
negative symptoms (and accompanied improvement in functioning);
possibly improvement of the other 48% of the patients for whom
improvement is possible and necessary is masked as the steady low
subgroup may average out effects for the other subgroups. This is clearlyvisible in Figs. 1 and 2, where the low subgroups show the same pattern
as the overall group but at a slightly lower level of symptoms and better
level of outcomes. The finding that some of the courses of outcomes
that appear visibly different were not significant (such as the differences
in living situation within ED) could indicate that other factors (such as
positive symptoms and neurocognition) are important for the level and
course of the outcomes as well, but it could also be due to reduced
power of subgroup analysis.
The few pharmacological studies to date do not yet provide enough
information for a firm conclusion about selective responsiveness to
treatment (Azorin et al., 2014; Kirkpatrick, 2014). Overall, there is only
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negative symptoms as a primary outcome (Elis et al., 2013), and the dif-
ferential effects on the subdomains are unclear. SA has been related to
the deficits in anticipatory pleasure (Buck and Lysaker, 2013; Foussias
et al., 2014b) which may make cognitive behavioral therapy a suitable
intervention to address defeatists beliefs (Staring et al., 2013). ED has
been linked to cognitive deficits (Bell et al., 2013; Ergül and Üçok,
2015; Hartmann-Riemer et al., 2015; Liemburg et al., 2013), which
may lead treatment development in the direction of restorative and/or
compensatory cognitive rehabilitation interventions. However, the sig-
nificant relation of ED with global functioning while controlling for cog-
nition indicates that cognition cannot fully explain this association.
Possibly, interventions targeting expressive skills such as Social Skills
Training (Bellack et al., 2004; Turner et al., 2014) could improve ED.4.4. Strengths, limitations and future directions
Strengths of this study are the large sample size, the longitudinal na-
ture and the used methodology. Several limitations should also be men-
tioned. We cannot infer causality from this observational study and we
do not know whether changes in negative symptoms are due to relief
of secondary negative symptoms. Although positive symptoms were in-
cluded as a confounder in this study, other factors may have caused sec-
ondary negative symptoms for which we were unable to control. This
may have influenced the observed patterns of the subgroups over time,
and treatment for patientswith secondary negative symptomswhich re-
quire a different approach than the suggested treatment strategies de-
scribed above (Carpenter et al., 1985). Also, the current results are
most applicable for those with predominant SA or ED (Strauss et al.,
2013). The relationship between ED and these aspects of functioning
should be further elucidated in future research, as our results may have
been affected by a conservative method to correct for multiple compari-
sons and possible power issues, because the high ED subgroup was very
small. Further, due to the rather large 3-year intervals capturing short
term changes and fluctuations is not possible with the current data. Fur-
thermore,measures for level of functioning and symptoms varied in time
prior to assessment, which may result in different conclusions with re-
spect to levels of functioning. In addition, there is a risk of selection
bias introduced by the relatively demanding protocol of the GROUP
study (Korver et al., 2012). Also, self-reported functioning can differ
from clinician-reported functioning, possibly due to limited awareness
of functional deficits (Bowie et al., 2007; Durand et al., 2015; Gould et
al., 2015). However, assessment of functioning with the GAF was
interviewed-based and living situation or engagement in work or study
is less prone to bias.
Future research should investigate possible causal mechanisms for
the variability in the subdomain levels over time, e.g. whether improve-
ment in negative symptoms facilitates improvements in outcome or vice
versa (Álvarez-Jiménez et al., 2012) and whether the subgroups differ
with regard to the care they (have) receive(d). A focus on persistent or
predominant negative symptoms, taking causes of secondary negative
symptoms into account, may help in better determining possible treat-
ment strategies, especially for those with themost severe levels of nega-
tive symptoms (Buchanan, 2007; Rabinowitz et al., 2013). For thosewith
co-occurring SA and ED, research into the influence of combinations of
SA and ED subgroups is needed, but this was beyond the scope of our
study. Research on more specific diagnostic groups could be of value as
well, since the low SA and low ED subgroup included significantly
fewer patients with schizophrenia.
In summary, our results show that there is a considerable heteroge-
neity in the course of the subdomains and that the course of the
subdomains is related to outcome. Research on treatments for negative
symptoms could benefit from distinguishing subgroups within SA and
ED to prevent a possible treatment effect to be masked by those steady
low levels of symptoms.Contributors
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